NEW YORK (TheStreet) -- TheStreet's Jim Cramer questions if Allergan
(AGN - Get Report) can fight off Valeant
(VRX - Get Report), and he will talk to Allegan CEO David Pyott on Wednesday.
Cramer thinks it is clear that Allergan is basing much of its independence on its pipeline, but he believes investors would take their money and run if this pipeline turns out to be not as good as Pyott has claimed.
Cramer suggests investors sell half of their position in Allergan and let the other half run. He thinks the stock would be closed to $120 or $125 if Valeant were not involved.
Must Watch: Jim Cramer: Allergan Would be at $120 if Valeant Wasn't Involved
AGN data by YCharts
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.